Dr. Wikenheiser-Brokamp of Cincinnati Children’s Hospital Medical Center was awarded an Established Investigator Award in 2022 for her project titled:  Identifying Cell-Cell Signaling Driving Pulmonary

One of the greatest challenges in caring for patients with lymphangioleiomyomatosis (LAM) is to find better ways to track disease progression, either off or on

PHONE CALLS TO CONGRESS NEEDED The LAM community has an opportunity to advocate for improved oxygen therapy through a simple phone call to their congressional

Lymphangioleiomyomatosis (LAM) is a complex lung disease characterized by cyst formation due to mutations in the TSC1/2 genes, leading to the overactivation of a molecular

Tuberous Sclerosis Complex (TSC) is a genetic disorder caused by mutations in the TSC1 or TSC2 gene, leading to the hyperactivation of the mechanistic target

The Board of Directors is pleased and excited to announce the appointment of Dr. Lyndsay Hoy as the inaugural Chief Mission Officer (CMO) of The

Dear LAM Community Members, The LAM Foundation prioritizes supporting LAM scientific research, funding a wide range of projects and initiatives. To maximize impact for LAM

“Rare diseases are often disregarded given their rarity. Most are underdiagnosed. The minute you tell clinicians that this is actually four to five times more

Dr. Vera Krymskaya has been appointed Scientific Director at The LAM Foundation after serving as interim since July 2023. She is the first female PhD

Dear LAM Community Members, The LAM Foundation prioritizes supporting LAM scientific research, funding a wide range of projects and initiatives. To maximize impact for LAM

The mTORC1 pathway is a signaling pathway in cells in the body that controls cell growth and survival. In many cancers and in LAM, this

LAM is caused by changes in some genes that control cell growth called the mTORC1 pathway. Cells use this pathway to make many copies of